CA2928665A1 - Formes cristallines de composes therapeutiques et utilisations de celles-ci - Google Patents

Formes cristallines de composes therapeutiques et utilisations de celles-ci Download PDF

Info

Publication number
CA2928665A1
CA2928665A1 CA2928665A CA2928665A CA2928665A1 CA 2928665 A1 CA2928665 A1 CA 2928665A1 CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A CA2928665 A CA 2928665A CA 2928665 A1 CA2928665 A1 CA 2928665A1
Authority
CA
Canada
Prior art keywords
less
equal
crystalline form
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2928665A
Other languages
English (en)
Inventor
Elizabeth M. Enlow
Minh Ngoc Nguyen
Winston Z. ONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kala Bio Inc
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/184,886 external-priority patent/US9353123B2/en
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Priority to CA3109285A priority Critical patent/CA3109285A1/fr
Publication of CA2928665A1 publication Critical patent/CA2928665A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
CA2928665A 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci Abandoned CA2928665A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3109285A CA3109285A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US61/898,741 2013-11-01
US14/184,886 2014-02-20
US14/184,886 US9353123B2 (en) 2013-02-20 2014-02-20 Therapeutic compounds and uses thereof
PCT/US2014/063630 WO2015066584A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composés thérapeutiques et utilisations de celles-ci

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3109285A Division CA3109285A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci

Publications (1)

Publication Number Publication Date
CA2928665A1 true CA2928665A1 (fr) 2015-05-07

Family

ID=53005242

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3109285A Abandoned CA3109285A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci
CA2928665A Abandoned CA2928665A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3109285A Abandoned CA3109285A1 (fr) 2013-11-01 2014-11-03 Formes cristallines de composes therapeutiques et utilisations de celles-ci

Country Status (5)

Country Link
EP (1) EP3062795A4 (fr)
JP (2) JP6426195B2 (fr)
AU (1) AU2014341966B2 (fr)
CA (2) CA3109285A1 (fr)
WO (1) WO2015066584A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3109285A1 (fr) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et utilisations de celles-ci
JP7108681B2 (ja) 2017-08-11 2022-07-28 アモーレパシフィック コーポレーション (r)‐n‐[1‐(3,5‐ジフルオロ‐4‐メタンスルホニルアミノ‐フェニル)‐エチル]‐3‐(2‐プロピル‐6‐トリフルオロメチル‐ピリジン‐3‐イル)‐アクリルアミドを含む医薬組成物
WO2020179837A1 (fr) 2019-03-04 2020-09-10 Ricoh Company, Ltd. Appareil et procédé de traitement de coopération
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
CA2473572C (fr) * 2002-02-01 2011-05-10 Astrazeneca Ab Composes de quinazoline
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
AU2014219024B2 (en) * 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
CA3109285A1 (fr) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et utilisations de celles-ci

Also Published As

Publication number Publication date
JP2019038824A (ja) 2019-03-14
AU2014341966B2 (en) 2017-08-17
EP3062795A4 (fr) 2017-05-31
WO2015066584A1 (fr) 2015-05-07
CA3109285A1 (fr) 2015-05-07
JP6426195B2 (ja) 2018-11-21
AU2014341966A1 (en) 2016-05-12
JP2016535779A (ja) 2016-11-17
EP3062795A1 (fr) 2016-09-07

Similar Documents

Publication Publication Date Title
US11713323B2 (en) Crystalline forms of therapeutic compounds and uses thereof
CA2871748C (fr) Nanoparticules pharmaceutiques a transport mucosal ameliore
US9688688B2 (en) Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP7058885B2 (ja) 尿素誘導体及びその使用
JP2019038824A (ja) 治療用化合物の結晶形態及びその使用
US20190023710A1 (en) Novel compounds and uses thereof
US9890173B2 (en) Crystalline forms of therapeutic compounds and uses thereof

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20210217